Heidelberg Pharma AG raises €34.4mAntibody-drug-conjugate (ADC) specialist Heidelberg Pharma AG has raised €34.4m through the issuance of 7,484,190 new shares at €2.60 and 14,968,380 convertible bonds with a nominal value of €1 … more ➔
Amsterdam applauded as new EMA headquartersAmsterdam has beaten Milan and Copenhagen in the race to become the European Medicines Agency’s new home. Pharma and biotech stakeholders applauded the vote as Amsterdam achieved the hightest rate of … more ➔
Roche chemo-immunotherapy combo meet NSCLC Phase III endpoint A Phase III study (IMpower150) sponsored by Roche has shown that a combo of the company’s PD-L1 blocker atezolizumab (Tecentriq) and VEGF blocking antibody bevacizumab (Avastin) plus paclitaxel + carboplatin … more ➔
Orphazyme raises €80m in oversubscribed IPODanish heat shock protein specialist Orphazyme raised €80m+ through an IPO at Nasdaq Copenhagen adding momentum to the current upswing of European biotech. more ➔
Antibiotic Resistance: EU SME alliance calls for specific support to thrive AMR R&DThe BEAM Alliance has called out worldwide stakeholders to support SME-driven innovation to revive the product pipeline fighting antimicrobial resistance (AMR). In a position paper the alliance … more ➔
Bayer inks US$1.55bn cancer deal with Loxo OncologyGerman Bayer AG has acquired ex-US commercialisation rights to Loxo Oncology Inc’s Phase II lead larotrectinib (LOXO-101), which targets TRK (tropomyosin receptor kinase) fusions in 17 cancer types, … more ➔
Bill Gates invests into Alzheimer’s R&D Billionaire Bill Gates announced he is going to invest US$50m private money into the Dementia Discovery Fund (DDF) to support fresh ideas for developing Alzheimer drugs and diagnostics. The venture … more ➔
CHMP recommends EU marketing approval of ten drugsThe European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended seven medicines for approval, including two orphan medicines, plus three generics at its November 2017 … more ➔
BIO-Europe more popular than ever More than 4,000 participants from all over the globe visited Berlin in early November to take part in this year’s BIO-Europe. The event continues to be on the upswing – like the biotech industry itself. more ➔
Spain pushes circular bioeconomyConversion of agricultural waste into useful products is a worldwide need. As part of the European Project Valor Plus, Spanish biotechindustry association ASEBIO invited its members to visit the recently … more ➔
